Author

J. Easton

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 7 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 7 Approach:experimental assay· 6 Research Focus:cell type annotation· 3 Research Focus:differential expression· 3 Research Focus:clustering· 2 Research Focus:drug response / drug discovery· 2 Research Focus:gene regulatory network inference· 2 Organism:mouse· 2

Frequent Co-Authors

M. Pan· 3 shared P. Geeleher· 3 shared B. Ju· 2 shared D. Yergeau· 2 shared E. Stewart· 2 shared H. Mulder· 2 shared H.-M. Lee· 2 shared J. Low· 2 shared

Activity by Year

2017-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

M. Pan

Mutual co-authors in cluster

Author profile →

8 papers

Recent·Most cited

An integrated single-cell RNA-seq map of human neuroblastoma tumors and preclinical models uncovers divergent mesenchymal-like gene expression programs.

R. H. Chapple, X. Liu, S. Natarajan, M. I. M. Alexander, Y. Kim, A. G. Patel, C. W. LaFlamme, M. Pan, W. C. Wright, H.-M. Lee, Y. Zhang, M. Lu, S. C. Koo, C. Long, J. Harper, , P. Geeleher

The paper compares mesenchymal-like gene expression programs in neuroblastoma preclinical models and patient tumors using single-cell RNA-seq and identifies chemotherapy-induced changes in PDX and GEMM.

bioRxiv · Apr 13, 2023Cancer Biology

A CRISPR-drug perturbational map for identifying new compounds to combine with commonly used chemotherapeutics.

H.-M. Lee, W. C. Wright, M. Pan, J. Low, D. Currier, J. Fang, S. Singh, S. Nance, I. Delahunty, Y. Kim, R. H. Chapple, Y. Zhang, X. Liu, J. A. Steele, J. Qi, , P. Geeleher

The paper uses CRISPR knockout screens to identify drug combinations that enhance the effectiveness of common chemotherapeutics in neuroblastoma cells.

bioRxiv · Apr 12, 2023Cancer Biology

NSD2 E1099K drives relapse in pediatric acute lymphoblastic leukemia by disrupting 3D chromatin organization

S. Narang, N. Evensen, J. Saliba, J. Pierro, M. L. Loh, P. A. Brown, H. Mulder, Y. Shao, J. Easton, X. Ma, A. Tsirigos, W. L. Carroll

This study shows NSD2 E1099K mutation disrupts 3D chromatin organization in B-ALL, leading to drug resistance and clonal evolution through compartmentalization changes.

bioRxiv · Feb 24, 2022 · PreprintCancer Biology

A Developmentally Prometastatic Niche to Hepatoblastoma in Neonatal Liver mediated by the Cxcl1/Cxcr2 Axis

L. Fan, Q. Pan, W. Yang, S. C. Koo, C. Tian, L. Li, M. Lu, A. Brown, B. Ju, J. Easton, S. Ranganathan, S. Shin, A. Bondoc, J. J. Yang, J. Yu, L. Zhu

This study identifies a neonatal liver niche that promotes hepatoblastoma metastasis via the Cxcl1/Cxcr2 axis, showing increased tumor aggressiveness and hypoxia in early postnatal models.

bioRxiv · Oct 22, 2021Cancer Biology

The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma.

M. Pan, C. Wright, R. Chapple, A. Zubair, M. Sandhu, J. Batchelder, J. Low, K. Blankenship, L. Wang, B. Gordon, P. Archer, S. W. Brady, S. Natarajan, M. Pozsgai, J. Schuetz, , P. Geeleher

This study identifies CX-5461 as a TOP2B inhibitor with selective activity in high-risk neuroblastoma but highlights safety concerns due to TOP2B off-target effects.

bioRxiv · Feb 25, 2021Cancer Biology

miR-424(322) is a molecular switch controlling pro-inflammatory vs anti-inflammatory skin DC subset differentiation by modulating TGF-β signaling

V. Zyulina, K.-K. Yan, B. Ju, C. Passegger, C. Tam-Amersdorfer, Q. Pan, T. Sconocchia, C. Pollack, B. Shaner, A. Zebisch, J. Easton, J. Yu, J. Silva, H. Strobl

This study identifies miR-424(322) as a molecular switch that controls the differentiation of pro-inflammatory monocyte-derived DCs (moDCs) versus anti-inflammatory Langerhans cells (LCs) by modulating TGF-β signaling.

bioRxiv · Sep 7, 2020 · PreprintImmunology

MYCN Amplification and ATRX Mutations are Incompatible in Neuroblastoma

M. Zeineldin, S. Federico, X. Chen, Y. Fan, B. Xu, E. Stewart, X. Zhou, J. Jeon, L. Griffiths, J. Easton, H. Mulder, D. Yergeau, Y. Liu, J. Wu, C. Van Ryn, , M. Dyer

The paper shows that ATRX mutations and MYCN amplification are mutually exclusive in neuroblastoma and lead to synthetic lethality.

bioRxiv · Jul 29, 2018Cancer Biology

Genome-wide Segregation of Single Nucleotide and Structural Variants into Single Leukemia Cells

J. Easton, V. Gonzalez-Pena, D. Yergeau, X. Ma, C. Gawad

The paper introduces a method to analyze single-cell variants in leukemia, finding structural variations precede single nucleotide changes in cancer development.

BMC Genomics · Nov 25, 2017Peer-reviewedCancer Biology